Quris Raises $9 Million in Seed Round  

by Kay Aloha Villamor in October 22nd, 2021

Quris, an Israeli company that is developing an AI platform to predict what drug candidates will work in humans, raised $9 million in Seed funding. 

The round was led by Dr. Judith Richter and Dr. Kobi Richter, professionals of cardiovascular intervention therapeutics, with participation from Moshe Yanai, a disruptive data-storage technology expert, and strategic angel investors.

The announcement of the funding coincided with the launch of its platform via a partnership with The New York Stem Cell Foundation (NYSCF) Research Institute. 

Company: Quris Technologies LTD.

Raised: $9.0M

Round: Seed Round

Funding Month: October 2021

Lead Investors: Dr. Judith Richter and Dr. Kobi Richter

Additional Investors: Moshe Yanai

Company Website: https://www.quris.ai/

Software Category: Clinician prediction AI platform

About the Company: Quris is an artificial intelligence innovator that is disrupting the drug development process. Quris machine-learning bio-platform better predicts which drug candidates will safely work in humans, avoiding the tremendous costs of failed clinical trials. Quris is led by a track-record team of top scientists and strategic investors. Its first AI-based drug is now prepping for clinical testing. The company currently has 18 granted and pending patents to help its platform use a combination of ‘minitarised biology’ chips and real-time nano-sensor and nano-circulation chips to train the Quris AI engine and drug candidate safety predictor. 

Source: https://www.calcalistech.com/ctech/articles/0,7340,L-3920715,00.html



Your cart